Toward wisdom from failure: Lessons from neuroprotective stroke trials and new therapeutic directions

Stroke

Volumn 33, Issue 8, 2002, Pages 2123-2136

  Gladstone, David J ^a   Black, Sandra E ^a   Hakim, Antoine M ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Cerebral ischemia; Clinical trials; Models, animal; Neuroprotection; Rehabilitation; Stroke; Translations

Indexed keywords

ANCROD; HEPARIN;

BRAIN INFARCTION; BRAIN ISCHEMIA; GRAY MATTER; HUMAN; MEASUREMENT; MEDICAL RESEARCH; NERVE CELL PLASTICITY; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT FAILURE; TREATMENT PLANNING; WHITE MATTER;

CELL DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; HUMANS; NEUROPROTECTIVE AGENTS; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 0036330007     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000025518.34157.51     Document Type: Review

References (226)

1. Burden of disease: Implications for future research
2. Trends in acute ischemic stroke trials through the 20th century
3. Tissue plasminogen activator for acute ischemic stroke
4. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: A randomized controlled trial: Prolyse in Acute Cerebral Thromboembolism
5. Low-molecular-weight heparin for the treatment of acute ischemic stroke
6. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: A randomized controlled trial: Stroke Treatment With Ancrod Trial
7. Current status and perspectives of neuroprotection in ischemic stroke treatment
8. An overview of acute stroke therapy: Past, present, and future
9. Neuroprotection of acute ischemic stroke: Where are we?
10. Neuroprotection and traumatic brain injury
11. Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations
12. Current status of neuroprotection trials for traumatic brain injury: Lessons from animal models and clinical studies
13. Challenges in translating the efficacy of neuroprotective agents in experimental models into knowledge of clinical benefits in head injured patients
14. Recommendations for standards regarding preclinical neuroprotective and restorative drug development
15. Recommendations for clinical trial evaluation of acute stroke therapies
16. Neuroprotection is unlikely to be effective in humans using current trial designs
17. Neuroprotection is unlikely to be effective in humans using current trial designs: An opposing view
18. The failure of neuronal protective agents versus the success of thrombolysis for the treatment of ischemic stroke. The predictive value of animal models
19. Neuroprotection for ischaemic stroke: An unattainable goal?
20. Why do neuroprotective drugs work in animals but not humans?
21. Neuroprotection
22. Neuroprotection for acute stroke: Making clinical trials work
23. Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy
24. Neuroprotection in acute ischaemic stroke: A tale of for whom the bell tolls?
25. Neuroprotection failure in stroke
26. Neuroprotection disappointment yet aGAIN
27. Neuroprotection in acute ischaemic stroke: Current status and future potential
28. Animal models of acute ischemic stroke: Can they predict clinically successful neuroprotective drugs?
29. What have we learned from clinical neuroprotective trials?
30. Neuroprotection: Past successes and future challenges
31. Animal models
32. Rodent models of stroke
33. Outcome measures in acute stroke trials: A systematic review and some recommendations to improve practice
34. Nimodipine in animal model experiments of focal cerebral ischemia: A systematic review
35. Ensuring patient safety in clinical trials for treatment of acute stroke
36. Aptiganel hydrochloride in acute ischemic stroke: A randomized controlled trial
37. Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial
38. Does effect of a neuroprotective agent on volume of experimental animal cerebral infarct predict effect of the agent on clinical outcome in human stroke?
39. Acute stroke therapy at the millennium: Consummating the marriage between the laboratory and bedside: The Feinberg lecture
40. Factors determining the therapeutic window for stroke
41. Early stroke treatment associated with better outcome: The NINDS rt-PA stroke study
42. Treatment of acute ischemic stroke, challenging the concept of a rigid and universal time window
43. Mapping the ischaemic penumbra with PET: Implications for acute stroke treatment
44. Characterizing the target of acute stroke therapy
45. Prolonged persistence of substantial volumes of potentially viable brain tissue after stroke: A correlative PET-CT study with voxel-based data analysis
46. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment With Alteplase to Reverse Stroke (STARS) study
47. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility
48. Neuroprotection of the brain during cardiopulmonary bypass
49. Prophylactic neuroprotection for cerebral ischemia
50. Prophylactic pharmacologic neuroprotection against focal cerebral ischemia
51. Evaluating neuroprotective agents for clinical anti-ischemic benefit using neurological and neuropsychological changes after cardiac surgery under cardiopulmonary bypass: Methodological strategies and results of a double-blind, placebo-controlled trial of GMI ganglioside
52. Perfusion thresholds in human cerebral ischemia: Historical perspective and therapeutic implications
53. Advances in neuroprotection trials
54. The cerebral ischemic penumbra
55. Ischemic penumbra: The therapeutic window
56. Which targets are relevant for therapy of acute ischemic stroke?
57. The ischemic penumbra: Operationally defined by diffusion and perfusion MRI
58. Ischemic penumbra: Evidence from functional imaging in man
59. Mapping the ischaemic penumbra with PET: A new approach
60. Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia
61. Magnetic resonance imaging of acute stroke
62. Absent middle cerebral artery flow predicts the presence and evolution of the ischemic penumbra
63. Use of diffusion and perfusion magnetic resonance imaging as a tool in acute stroke clinical trials
64. Sipatrigine in Stroke Trial: A European multicenter study to establish the maximum tolerated dose of sipatrigine and to assess the efficacy of that dose by measuring the change in volume of ischaemic lesion by magnetic resonance imaging
65. Perfusion mapping using computed tomography allows accurate prediction of cerebral infarction in experimental brain ischemia
66. A three-item scale for the early prediction of stroke recovery
67. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke
68. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy: ASPECTS Study Group: Alberta Stroke Programme Early CT Score
69. New imaging strategies for patient selection for thrombolytic and neuroprotective therapies
70. Using pathophysiology in acute stroke trials
71. Drug development for stroke: Importance of protecting cerebral white matter
72. Anoxic and ischemic injury of myelinated axons in CNS white matter: From mechanistic concepts to therapeutics
73. The N-methyl-D-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats
74. Both NMDA and non-NMDA subtypes of glutamate receptors are concentrated at synapses on cerebral cortical neurons in culture
75. NMDA receptor blockade fails to alter axonal injury in focal cerebral ischemia
76. Duration of neuroprotective treatment for ischemic stroke
77. Progression of ischaemic stroke and excitotoxic amino acids
78. Massive persistent release of excitatory amino acids following human occlusive stroke
79. Continuing ischemic damage after acute middle cerebral artery infarction in humans demonstrated by short-echo proton spectroscopy
80. Pharmacology of recovery after stroke
81. Stroke recovery
82. Stroke recovery
83. Early GABA-Ergic Activation Study in Stroke (EGASIS)
84. Reemergence of stroke deficits with midazolam challenge
85. Rapid dendritic morphogenesis in CA1 hippocampal dndrites induced by synaptic activity
86. The Glycine Antagonist in Neuroprotection Americas Investigators: Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: A randomized controlled trial
87. To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents?
88. The problem of assessing effective neuroprotection in experimental cerebral ischemia
89. Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction in the rat
90. Intracisternal osteogenic protein-1 enhances functional recovery following focal stroke
91. Long-term functional end points following middle cerebral artery occlusion in the rat
92. Functional assessments in mice and rats after focal stroke
93. Neuropathological endpoints in experimental stroke pharmacotherapy: The importance of both early and late evaluation
94. Continuing postischemic neuronal death in CA1: Influence of ischemia duration and cytoprotective doses of NBQX and SNX-III in rats
95. Inhibition of cyclin dependent kinases improves CA1 neuronal survival and behavioral performance following global ischemia in the rat
96. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat
97. Neuronal necrosis after middle cerebral artery occlusion in Wistar rats progresses at different time intervals in the caudoputamen and the cortex
98. Long-lasting neuroprotective effect of postischemic hypothermia and treatment with an anti-inflammatory/antipyretic drug: Evidence for chronic encephalopathic processes following ischemia
99. Cerebral ischemia: From animal studies to clinical practice: Should the methods be reviewed?
100. Predictors of stroke outcome
101. Potentially reversible factors during the very acute phase of stroke and their impact on the prognosis: Is there a large therapeutic potential to be explored?
102. Systematic review of prognostic models in patients with acute stroke
103. Early stroke: A dynamic process
104. The role of hyperglycemia in acute stroke
105. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke
106. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: A systematic overview
107. Clomethiazole Acute Stroke Study (CLASS): Results of a randomized, controlled trial of Clomethiazole versus placebo in 1360 acute stroke patients
108. The Clomethiazole Acute Stroke Study (CLASS): Efficacy results in a subgroup of 545 patients with total anterior circulation syndrome
109. Clomethiazole Acute Stroke Study in Ischemic Stroke (CLASS-I): Final results
110. Assessment of clinical outcomes in acute stroke trials
111. Defining post-stroke recovery: Implications for design and interpretation of drug trials
112. Entry criteria and baseline characteristics predict outcome in acute stroke trials
113. Use of the Barthel Index and modified Rankin Scale in acute stroke trials
114. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial
115. A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: Preliminary reliability and validity
116. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
117. Stroke recovery profile and the modified Rankin assessment
118. Neurological deterioration as a potential alternative endpoint in human clinical trials of experimental pharmacological agents for treatment of severe traumatic brain injuries: Executive Committee of the International Selfotel Trial
119. Transplantation of cultured human neuronal cells for patients with stroke
120. The poststroke hemiplegic patient
121. The Fugl-Meyer Assessment of motor recovery after stroke: A critical review of its measurement properties
122. The stroke impact scale version 2.0. Evaluation of reliability, validity, and sensitivity to change
123. Development of a stroke-specific quality of life scale
124. Molecular and cellular therapies for stroke recovery
125. Prediction of functional outcome after stroke: Comparison of the Orpington Prognostic Scale and the NIH Stroke Scale
126. Mega trials versus small trials in stroke
127. Bayes offers a "new" way to make sense of numbers
128. The future of stroke treatment
129. Pathobiology of ischaemic stroke: An integrated view
130. The changing landscape of ischaemic brain injury mechanisms
131. Stroke
132. Brain plasticity and stroke rehabilitation: The Willis Lecture
133. Apoptosis and cerebral ischemia
134. Caspases as treatment targets in stroke and neurodegenerative diseases
135. Apoptosis after experimental stroke: Fact or fashion?
136. Very delayed infarction after mild focal cerebral ischemia: A role for apoptosis?
137. Blockade of glutamate receptors unmasks neuronal apoptosis after oxygen-glucose deprivation in vitro
138. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage
139. Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation
140. Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia
141. Thrombolysis in ischaemic stroke: Present and future: Role of combined therapy
142. The concept of combination therapy in acute ischemic stroke
143. A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke
144. Non-pharmacologic (physiologic) neuroprotection in the treatment of brain ischemia
145. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model
146. Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model
147. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke
148. Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model
149. Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats
150. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy
151. Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat
152. The Clomethiazole Acute Stroke Study in Tissue-Type Plasminogen Activator-Treated Stroke (CLASS-T): Final results
153. Combination Therapy Stroke Trial: Recombinant tissue-type plasminogen activator with/without lubeluzole
154. Synergistic combinatorial stroke therapy: A quantal bioassay of a GABA agonist and a glutamate antagonist
155. Combination therapy protects ischemic brain in rats a glutamate antagonist plus a gamma-aminobutyric acid agonist
156. Combination chemotherapy extends the therapeutic window to 60 minutes after stroke
157. Combination therapy with MK-801 and alpha-phenyl-tert-butyl-nitrone enhances protection against ischemic neuronal damage in organotypic hippocampal slice cultures
158. Combined therapy with MK-801 and nimodipine for protection of ischemic brain damage
159. Synergistic effects of citicoline and MK-801 in temporary experimental focal ischemia in rats
160. bFGF enhances the protective effects of MK-801 against ischemic neuronal injury in vitro
161. Neuroprotective effects of combination therapy with tirilazad and magnesium in rats subjected to reversible focal cerebral ischemia
162. Combination drug therapy and mild hypothermia: A promising treatment strategy for reversible, focal cerebral ischemia
163. Neuroprotective efficacy of combination therapy with two different antioxidants in rats subjected to transient focal ischemia
164. Synergistic effects of a combination of low-dose bFGF and citicoline after temporary experimental focal ischemia
165. Additive neuroprotective effects of dextrorphan and cycloheximide in rats subjected to transient focal cerebral ischemia
166. Synergistic effects of caspase inhibitors and MK-801 in brain injury after transient focal cerebral ischaemia in mice
167. Synergistic protective effect of caspase inhibitors and bFGF against brain injury induced by transient focal ischaemia
168. Enhancing recovery after stroke with noradrenergic pharmacotherapy: A new frontier?
169. Dendritic spines lost during glutamate receptor activation reemerge at original sites of synaptic contact
170. Recovery recapitulates ontogeny
171. Growth factors and cerebral ischemia
172. Recovery and repair issues after stroke from the scientific perspective
173. Mechanisms underlying functional recovery following stroke
174. Cell proliferation and differentiation from ependymal, subependymal and choroid plexus cells in response to stroke in rats
175. Neural stem cells in the adult mammalian forebrain: A relatively quiescent subpopulation of subependymal cells
176. Time window of intracisternal osteogenic protein-1 in enhancing functional recovery after stroke
177. Pharmacological approaches to stroke recovery
178. Trafermin in acute stroke: Results of a phase II/III randomized efficacy study
179. Fibroblast (trafermin) in acute stroke: Results of the European-Australian phase II/III safety and efficacy trial
180. Recovery recapitulates ontogeny
181. Cyclin-dependent kinases as a therapeutic target for stroke
182. Treatment of stroke in rat with intracarotid administration of marrow stromal cells
183. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats
184. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats
185. Recovery after damage to motor cortical areas
186. Role of adaptive plasticity in recovery of function after damage to motor cortex
187. Neural substrates for the effects of rehabilitative training on motor recovery after ischemic infarct
188. Reorganization of movement representations in primary motor cortex following focal ischemic infarcts in adult squirrel monkeys
189. Intensity of leg and arm training after primary middle-cerebral-artery stroke: A randomised trial
190. Constraint-induced movement therapy for motor recovery in chronic stroke patients
191. Bilateral movement enhances ipsilesional cortical activity in acute stroke: A pilot fMRI Study
192. Body weight-supported treadmill training after stroke
193. Influence of common drugs and related factors on stroke outcome
194. Potential effects of common drugs on stroke recovery
195. Neurorehabilitation: Greater plasticity through chemicals and practice
196. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury
197. Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat
198. Post-lesion practice and amphetaminefacilitated recovery of beam-walking in the rat
199. Norepinephrine depletion impairs motor recovery following sensorimotor cortex injury in the rat
200. Modulation of long-term potentiation by peripherally administered amphetamine and epinephrine
201. Neocortical neural sprouting, synaptogenesis, and behavioral recovery after neocortical infarction in rats
202. Enhanced neocortical neural sprouting, synaptogenesis, and behavioral recovery with d-amphetamine therapy after neocortical infarction in rats
203. Enhanced CREB phosphorylation and changes in cFOS and FRA expression in striatum accompany amphetamine-induced sensitization
204. Modulation of use-dependent plasticity by d-amphetamine
205. Pharmacotherapy for recovery of function after brain injury
206. Rehabilitation pharmacology: Noradrenergic enhancement of physical therapy
207. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients
208. Amphetamine paired with physical therapy accelerates motor recovery after stroke
209. Dextroamphetamine paired with standard and robotic neurorehabilitation changes motor performance one day later
210. Enhancing recovery from hemiplegic stroke: Design of a multicentre study of amphetamine-facilitated stroke rehabilitation
211. A double-blind placebo-controlled study of the effects of amphetamine and physiotherapy after stroke
212. A double-bind, placebo-controlled study of the use of amphetamine in the treatment of aphasia
213. Use of pharmacotherapy in the treatment of aphasia
214. Pharmacotherapy in the treatment of aphasia
215. Methylphenidate in early poststroke recovery: A double-blind, placebocontrolled study
216. The norepinephrine precursor L-threo-3,4-dihydroxyphenylserine facilitates motor recovery in chronic stroke patients
217. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: A prospective, randomised, double-blind study
218. Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy
219. Physician prescribing patterns following hospital admission for ischemic cerebrovascular disease
220. Prescribing of potentially harmful drugs to patients admitted to hospital after head injury
221. Common drugs may influence motor recovery after stroke
222. Effects of commonly prescribed medications on stroke recovery: A TOAST study analysis
223. Haloperidol, thiazides and some antihypertensives slow recovery from aphasia